PanoHealth’s testing facility is compliant in Good Laboratory Practice (GLP) and ISO-13485 certified. The Quantibody® technology used is a proprietary technology which allows for the rapid and accurate analysis of biomarkers present in the blood. It works by using antibodies that tightly bind to the biomarkers and allow for their detection. Quantibody® technology has now been developed to simultaneously test over 1,000 biomarkers, yielding valuable information pertaining to many different physiological or disease states.
Quantibody® employs a matched pair of antibodies for protein biomarker detection. A panel of capture antibodies is printed on a glass slide. After a blocking step, samples are incubated on the arrays. Proteins specific to the capture antibodies are bound to the slide, and the nonspecific proteins are then washed off. The arrays are incubated with a cocktail of biotinylated detection antibodies, followed by a streptavidin-conjugated fluorescence marker. This creates green-fluorescent signals which are visualized using a fluorescence laser scanner. The intensity of the fluorescent signals indicates the amount of the protein biomarkers on the glass slide array. This process of measuring specific amounts of protein molecules is called Quantitative Proteomics.